App-Quantinova.ai

Assessment of longer‐term efficacy, safety, and haematological improvement in the phase 3, randomised, double‐blind, placebo‐controlled MEDALIST trial of luspatercept to treat anaemia in patients with lower‐risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions

G. J. Mufti - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myelodysplastic Syndrome

luspatercept

Evaluating luspatercept responders in the phase 3, randomised, double‐blind, placebo‐controlled BELIEVE trial of luspatercept in adult beta‐thalassaemia patients who require regular red blood cell transfusions

J. Porter - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

luspatercept

Unilateral versus bilateral peripheral access using ultrasound machine guidance in patients undergoing red blood cell exchange transfusion: a comparative results

R. Valeza - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Breakthrough hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: results of a 52‐week extension from two phase 3 studies

A. Hill - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Paroxysmal nocturnal hemoglobinuria

Eculizumab

Patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab in the UK

J. Devin Peipert - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

Comparison of lost productivity due to eculizumab and ravulizumab treatments for paroxysmal nocturnal hemoglobinuria in France, Germany, Italy, Russia, Spain, the UK, and the USA

A. R. Levy - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

Hydroxyurea therapy does not impact TCD velocity in the East London sickle cell newborn cohort study

C. Sangarappillai - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sickle cell anemia

Hydroxyurea

Haemoglobin distribution width is low in alcoholic liver disease

N. Whitehouse - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Macrocytosis

N/A

Transcranial doppler long‐term follow‐up in children with sickle cell disease

I. Liguoro - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sickle cell anemia

Hydroxycarbamide

A retrospective laboratory assessment of the pyruvate kinase enzyme assay and analysis of 10 novel variants

C. Laas - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Pyruvate kinase (PK) deficiency

N/A

Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower‐risk myelodysplastic syndromes enrolled in the MEDALIST trial

G. J. Mufti - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

Erythropoietin

Plasma MicroRNAs dysregulation in postpartum pre‐eclamptic women: implication for the development of cardiovascular disease events and deep vein thrombosis later in life?

F. Abad - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Deep vein thrombosis

N/A

Prothrombin complex concentrate versus fresh frozen plasma in adults undergoing heart surgery (PROPHESY) ‐ a pragmatic pilot randomized controlled trial

L. Green - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Prothrombin complex

Platelet storage pool disease with excessive bleeding associated with a novel FLI1 variant

P. Bignell - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Macrothrombocytopenia

N/A

Shear flow‐based assay with HUVECs shows von Willebrand Factor (VWF) strings anchored to the endothelial surface and platelet aggregation in acute immune‐mediated Thrombotic Thrombocytopenic Purpura

C. Vendramin - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombotic thrombocytopenic purpura

histamine

Investigation of von Willebrand factor polymorphisms in congenital thrombotic thrombocytopenic purpura

C. Lupo - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombotic thrombocytopenic purpura

N/A

Prospective cohort study of haemostatic activation markers and correlation with bleeding and thrombotic complications in patients receiving Veno‐Venous Extra‐Corporeal Membrane Oxygenation (VV‐ECMO) ‐HAE study

D. Jayakody Arachchillage - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Heparin

Factor VIII levels and bleeding according to factor 8 mutation in pregnant carriers of haemophilia A: a multi‐centre retrospective cohort study

A. Collins - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Hemophilia

FVIII

A fast and simple UPLC‐MS/MS method for the simultaneous quantification of apixaban, edoxaban and rivaroxaban in human plasma and breast milk: for investigating direct oral anticoagulants in emerging lactation studies

Y. Zhao - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

rivaroxaban

EDTA‐associated platelet degranulation and thrombocytopenia mimics grey platelet syndrome

K. Burley - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Gray platelet syndrome

Heparin

Filters

45280 Abstracts